QbDVision is a technology company.
QbDVision is a cutting-edge platform designed specifically for biotech products, teams, and processes, focusing on digital product life cycle management for pharma and biotech.
QbDVision has raised $28.0M across 2 funding rounds.
QbDVision has raised $28.0M in total across 2 funding rounds.
QbDVision has raised $28.0M in total across 2 funding rounds.
QbDVision's investors include Breakout Ventures, Northpond Ventures.
QbDVision is a digital biotech company providing a cloud-based Digital CMC™ platform tailored for pharmaceutical and biotechnology manufacturing. It centralizes fragmented product and process knowledge into a searchable hub, automating workflows to accelerate drug development, ensure compliance, and enhance decision-making across the product lifecycle from R&D to commercial manufacturing.[1][2][3][5] Serving enterprise pharma and biotech teams—including three of the top six global companies—the platform solves inefficiencies from scattered data in emails, spreadsheets, and legacy systems, reducing cycle times and quality risks while enabling AI-powered insights and regulatory readiness.[3][5][6] With 28 employees, offices in Austin (HQ), Boston, and Dublin, and a recent $13M funding round, QbDVision demonstrates strong growth momentum through global deployments and customer wins.[2][3][7]
QbDVision was founded by industry veterans with over 100 years of combined experience in process development, pharmaceutical quality, and regulatory compliance, who recognized the need for modern digital tools in biopharma.[1][2][5][7] Frustrated by legacy challenges like unstructured data slowing drug development, they created a purpose-built platform to unify knowledge, streamline processes, and boost technical success rates.[5][6][7] Early traction came from addressing real-world pain points in CMC (chemistry, manufacturing, and controls), leading to rapid enterprise adoption and a $13M strategic investment in 2025, fueled by top customer acquisitions and global rollouts.[3][7]
QbDVision rides the wave of digital transformation in biopharma, where geopolitical uncertainty and industry growth demand CMC modernization beyond mere data strategies toward knowledge-based processes.[3][5] Its timing aligns with surging needs for AI integration in drug development, workflow automation, and efficient manufacturing amid rising therapy complexity and regulatory pressures.[1][3][6] By pioneering the Digital CMC category, it influences the ecosystem through global deployments, enabling faster breakthroughs, standardized processes, and AI readiness—positioning biopharma to deliver next-gen therapies more predictably.[2][3][7]
With fresh $13M capital, QbDVision is primed to expand its enterprise footprint, deepen AI capabilities, and solidify Digital CMC leadership amid biopharma's push for operational efficiency.[3] Trends like AI-driven intelligence, cloud security, and lifecycle automation will propel its growth, potentially capturing more market share as data silos crumble. Its influence could evolve from innovator to standard-setter, empowering more therapies to patients faster—echoing its founding mission to unlock biopharma's full scientific potential.[5][7]
QbDVision has raised $28.0M across 2 funding rounds. Most recently, it raised $13.0M Series A in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2025 | $13.0M Series A | Breakout Ventures, Northpond Ventures | |
| Feb 1, 2022 | $15.0M Series A | Breakout Ventures, Northpond Ventures |